Association study between cervical lesions and single or multiple vaccine-target and non-vaccine target human papillomavirus (HPV) types in women from northeastern Brazil

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Chagas, Bárbara Simas ^a   Comar, Manola ^b   Gurgel, Ana Pavla Almeida Diniz ^a   Paiva, Sérgio ^a   Seraceni, Silva ^b,c   De Freitas, Antonio Carlos ^a   Crovella, Sergio ^b,c  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPING TECHNIQUE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 66; INFECTION RISK; MAJOR CLINICAL STUDY; MIDDLE AGED; MIXED INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CYTOLOGY; WART VIRUS; IMMUNOLOGY; PAPILLOMAVIRIDAE; PHYSIOLOGY; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU; VIROLOGY;

WART VIRUS VACCINE;

ADULT; BRAZIL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX;

EID: 84941364520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132570     Document Type: Article

References (69)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011; doi: 10.1093/annonc/mdr015
2. Zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology. 2009; 384: 260-265. doi: 10.1016/j.virol.2008.11.046 PMID: 19135222
3. De Freitas AC, Gurgel APAD, Chagas BS, Coimbra EC, do Amaral CMM. Susceptibility to cervical cancer: An overview. Gynecol Oncol. 2012; 126: 304-311. doi: 10.1016/j.ygyno.2012.03.047 PMID: 22484226
4. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-350. doi: 10.1038/nrc798 PMID: 12044010
5. De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a metaanalysis. Lancet Infect Dis. 2007; 7: 453-459. doi: 10.1016/S1473-3099(07)70158-5 PMID: 17597569
6. De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048-1056. doi: 10.1016/S1470-2045(10)70230-8 PMID: 20952254
7. De Vincenzo R, Ricci C, Conte C, Scambia G. HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol Oncol. 2013; 130: 642-651. doi: 10.1016/j.ygyno.2013.05.033 PMID: 23747835
8. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-Specific HPV Infection and Multiple HPV Types: Prevalence and Risk Factor Profile in Nearly 12, 000 Younger and Older Danish Women: Sex Transm Dis. 2008; 35: 276-282. doi: 10.1097/OLQ.0b013e31815ac5c7 PMID: 18091564
9. Ah Lee S, Kang D, Soo Seo S, Kim Jeong J, Young Yoo K, Tark Jeon Y, et al. Multiple HPV infection in cervical cancer screened by HPVDNAChipTM. Cancer Lett. 2003; 198: 187-192. doi: 10.1016/S0304- 3835(03)00312-4 PMID: 12957357
10. Mejlhede N, Bonde J, Fomsgaard A. High frequency of multiple HPV types in cervical specimens from Danish women. APMIS. 2009; 117: 108-114. doi: 10.1111/j.1600-0463.2008.00019.x PMID: 19239432
11. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004; 57: 68-72. doi: 10.1136/jcp.57.1.68 PMID: 14693839
12. Dickson EL, Vogel RI, Bliss RL, Downs LS. Multiple-Type Human Papillomavirus (HPV) Infections: A Cross-Sectional Analysis of the Prevalence of Specific Types in 309, 000 Women Referred for HPV Testing at the Time of Cervical Cytology. Int J Gynecol Cancer. 2013; 23: 1295-1302. doi: 10.1097/ IGC.0b013e31829e9fb4 PMID: 23970156
13. Dickson EL, Vogel RI, Geller MA, Downs LS Jr.. Cervical cytology and multiple type HPV infection: A study of 8182 women ages 31-65. Gynecol Oncol. 2014; 133: 405-408. doi: 10.1016/j.ygyno.2014.03. 552 PMID: 24657488
14. Carozzi F, Ronco G, Gillio-Tos A, Marco LD, Mistro AD, Girlando S, et al. Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Eur J Cancer. 2012; 48: 1633-1637. doi: 10.1016/j.ejca.2011.10.010 PMID: 22088483
15. Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011; 128: 927-935. doi: 10.1002/ijc.25396 PMID: 20473886
16. Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011; 203: 910-920. doi: 10.1093/infdis/jiq139 PMID: 21402543
17. Resende LS, Rabelo-Santos SH, Sarian LO, Alves RR, Ribeiro AA, Zeferino LC, et al. A portrait of single and multiple HPV type infections in Brazilian women of different age strata with squamous or glandular cervical lesions. BMC Infect Dis. 2014; 14: 214. doi: 10.1186/1471-2334-14-214 PMID: 24751127
18. Beca F, Pinheiro J, Rios E, Pontes P, Amendoeira I. Genotypes and prevalence of HPV single and multiple concurrent infections in women with HSIL. Diagn Cytopathol. 2014; 42: 919-923. doi: 10.1002/dc. 23143 PMID: 24623593
19. Gurgel APAD, Chagas BS, do Amaral CMM, Albuquerque EMB, Serra IGSS, Silva Neto J da C, et al. Prevalence and genetic variability in capsid L1 gene of rare human papillomaviruses (HPV) found in cervical lesions of women from North-East Brazil. BioMed Res Int. 2013; 2013: 546354. doi: 10.1155/ 2013/546354 PMID: 23865057
20. Baldez da Silva MFPT, Chagas BS, Guimarães V, Katz LMC, Felix PM, Miranda PM, et al. HPV31 and HPV33 incidence in cervical samples from women in Recife, Brazil. Genet Mol Res GMR. 2009; 8: 1437-1443. doi: 10.4238/vol8-4gmr677
21. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2006; 15: 1274-1280. doi: 10.1158/1055- 9965.EPI-06-0129
22. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13: 100-110. doi: 10.1016/S1470-2045(11)70287-X PMID: 22075170
23. Malagón T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12: 781-789. doi: 10.1016/S1473-3099(12)70187-1 PMID: 22920953
24. Goldstone SE, Jessen H, Palefsky JM, Giuliano AR, Moreira ED Jr., Vardas E, et al. Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine. 2013; 31: 3849-3855. doi: 10.1016/j.vaccine.2013.06.057 PMID: 23831322
25. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13: 89-99. doi: 10.1016/S1470-2045(11)70286-8 PMID: 22075171
26. Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/ 18 vaccine trial. Vaccine. 2014; 32: 5087-5097. doi: 10.1016/j.vaccine.2014.06.038 PMID: 25018097
27. Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014; 110: 2804-2811. doi: 10.1038/bjc.2014.198 PMID: 24736582
28. Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014; 14: 958-966. doi: 10.1016/S1473-3099(14)70841-2 PMID: 25107680
29. Cómbita A, Duarte D, Rodríguez J, Molano M, Martínez L, Romero P, et al. Evaluation of the immune response to human papillomavirus types 16, 18, 31, 45 and 58 in a group of Colombian women vaccinated with the quadrivalent vaccine. Rev Colomb Cancerol. 2013; 17: 103-110. doi: 10.1016/S0123- 9015(13)70012-X
30. Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, et al. Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction. Pediatrics. 2012; peds.2011-3587. doi: 10.1542/peds.2011-3587
31. Orlando PA, Gatenby RA, Giuliano AR, Brown JS. Evolutionary Ecology of Human Papillomavirus: Trade-offs, Coexistence, and Origins of High-Risk and Low-Risk Types. J Infect Dis. 2012; 205: 272-279. doi: 10.1093/infdis/jir717 PMID: 22090448
32. Gheit T, Landi S, Gemignani F, Snijders PJF, Vaccarella S, Franceschi S, et al. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol. 2006; 44: 2025-2031. doi: 10.1128/ JCM.02305-05 PMID: 16757593
33. Comar M, Iannacone MR, Casalicchio G, McKay-Chopin S, Tommasino M, Gheit T. Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative pap test results and atypical squamous cells of undetermined significance. J Clin Microbiol. 2012; 50: 4041-4046. doi: 10.1128/JCM.02105-12 PMID: 23035194
34. Munagala R, Donà MG, Rai SN, Jenson AB, Bala N, Ghim SJ, et al. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int J Oncol. 2009; 34: 263-271. PMID: 19082497.
35. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 24 Suppl 1: S1-15. doi: 10.1016/j.vaccine.2005.09.054 PMID: 16406226
36. Pista A, Oliveira A, Verdasca N, Ribeiro F. Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women. Clin Microbiol Infect. 2011; 17: 941-946. doi: 10.1111/j.1469- 0691.2010.03387.x PMID: 21040156
37. Baldez da Silva MFPT, Guimarães V, Silva MAR, Medeiros do Amaral CM, Beçak W, Stocco RC, et al. Frequency of human papillomavirus types 16, 18, 31, and 33 and sites of cervical lesions in gynecological patients from Recife, Brazil. Genet Mol Res GMR. 2012; 11: 462-466. doi: 10.4238/2012.March.1.3
38. de M Fernandes TAA, de V Meissner R, Bezerra LF, de Azevedo PRM, Fernandes JV. Human papillomavirus infection in women attended at a cervical cancer screening service in Natal, Brazil. Braz J Microbiol. 2008; 39: 573-578. doi: 10.1590/S1517-83822008000300031 PMID: 24031268
39. Castro MM, Farias IP, Borborema-Santos CM, Correia G, Astolfi-Filho S. Prevalence of human papillomavirus (HPV) type 16 variants and rare HPV types in the central Amazon region. Genet Mol Res GMR. 2011; 10: 186-196. doi: 10.4238/vol10-1gmr992
40. Veríssimo Fernandes J, de Vasconcellos Meissner R, Goretti Freire Carvalho M, Araújo de Medeiros Fernandes TA, Medeiros Azevedo PR, Weber Veríssimo de Azevedo J, et al. Human papillomavirus prevalence in women with normal cytology and with cervical cancer in Natal, Brazil. Mol Med Rep. 2011; 4: 1321-1326. doi: 10.3892/mmr.2011.579 PMID: 21887467
41. Alencar TR, Cerqueira DM, Cruz MR da, Wyant PS, Ramalho ED, Martins CRF. New HPV-16 European and non-European variants in Central Brazil. Virus Genes. 2006; 35: 1-4. doi: 10.1007/s11262- 006-0040-5 PMID: 17048111
42. Cruz MR, Cerqueira DM, Cruz WB, Camara GNL, Brígido MM, Silva EO, et al. Prevalence of human papillomavirus type 16 variants in the Federal District, Central Brazil. Mem Inst Oswaldo Cruz. 2004; 99: 281-282. /S0074-02762004000300007 PMID: 15273800
43. Fernandes JV, Meissner RV, Carvalho MG, Fernandes TA, Azevedo PR, Sobrinho JS, et al. Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil. BMC Res Notes. 2010; 3: 96. doi: 10.1186/1756-0500-3- 96 PMID: 20377903
44. de M Fernandes TAA, de V Meissner R, Bezerra LF, de Azevedo PRM, Fernandes JV. Human papillomavirus infection in women attended at a cervical cancer screening service in Natal, Brazil. Braz J Microbiol. 2008; 39: 573-578. doi: 10.1590/S1517-83822008000300031 PMID: 24031268
45. Freitas LB, Chen Z, Muqui EF, Boldrini NAT, Miranda AE, Spano LC, et al. Human Papillomavirus 16 Non-European Variants Are Preferentially Associated with High-Grade Cervical Lesions. PLoS ONE. 2014; 9: e100746. doi: 10.1371/journal.pone.0100746 PMID: 24983739
46. Chagas BS, Batista MV de A, Crovella S, Gurgel APAD, Silva Neto J da C, Serra IGSS, et al. Novel E6 and E7 oncogenes variants of human papillomavirus type 31 in Brazilian women with abnormal cervical cytology. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2013; 16: 13-18. doi: 10.1016/j. meegid.2013.02.001
47. Chagas BS, Batista MVA, Guimarães V, Balbino VQ, Crovella S, Freitas AC. New variants of E6 and E7 oncogenes of human papillomavirus type 31 identified in Northeastern Brazil. Gynecol Oncol. 2011; 123: 284-288. doi: 10.1016/j.ygyno.2011.07.008 PMID: 21802716
48. Berumen J, Ordoñez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst. 2001; 93: 1325-1330. PMID: 11535707
49. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013; 445: 232-243. doi: 10.1016/j.virol.2013.07.018 PMID: 23998342
50. Burk RD, Terai M, Gravitt PE, Brinton LA, Kurman RJ, Barnes WA, et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res. 2003; 63: 7215-7220. PMID: 14612516
51. Burroni E, Bisanzi S, Sani C, Puliti D, Carozzi F. Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix. J Med Virol. 2013; 85: 83-90. doi: 10.1002/jmv.23417 PMID: 23124863
52. Chang Y-J, Chen H-C, Lee B-H, You S-L, Lin C-Y, Pan M-H, et al. Unique variants of human papillomavirus genotypes 52 and 58 and risk of cervical neoplasia. Int J Cancer J Int Cancer. 2011; 129: 965-973. doi: 10.1002/ijc.25724
53. Chansaenroj J, Theamboonlers A, Junyangdikul P, Swangvaree S, Karalak A, Poovorawan Y. Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac J Cancer Prev APJCP. 2012; 13: 599-606.
54. Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, et al. Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol. 2012; 86: 6855-6861. doi: 10.1128/JVI.00483-12 PMID: 22491459
55. Cornet I, Gheit T, Clifford GM, Combes J-D, Dalstein V, Franceschi S, et al. Human papillomavirus type 16 E6 variants in France and risk of viral persistence. Infect Agent Cancer. 2013; 8: 4. doi: 10.1186/ 1750-9378-8-4 PMID: 23343041
56. Gheit T, Cornet I, Clifford GM, Iftner T, Munk C, Tommasino M, et al. Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2011; 20: 1315-1321. doi: 10.1158/1055-9965.EPI-10-1187
57. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer J Int Cancer. 1996; 69: 364-368. doi: 10.1002/(SICI)1097-0215(19961021) 69:5<364::AID-IJC2>3.0.CO;2-3
58. Quint KD, de Koning MNC, van Doorn L-J, Quint WGV, Pirog EC. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol. 2010; 117: 297-301. doi: 10.1016/j.ygyno.2010.02.003 PMID: 20207397
59. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, et al. A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. Cancer Res. 2010; 70: 3159-3169. doi: 10.1158/0008-5472.CAN-09-4179 PMID: 20354192
60. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer J Int Cancer. 2007; 120: 1763-1768. doi: 10.1002/ijc.22481
61. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol. 2000; 81: 2959-2968. PMID: 11086127
62. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol. 1997; 71: 2463-2472. PMID: 9032384
63. Zehbe I, Lichtig H, Westerback A, Lambert PF, Tommasino M, Sherman L. Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential. Mol Cancer. 2011; 10: 77. doi: 10.1186/1476- 4598-10-77 PMID: 21702904
64. Zuna RE, Tuller E, Wentzensen N, Mathews C, Allen RA, Shanesmith R, et al. HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer. Infect Agent Cancer. 2011; 6: 19. doi: 10.1186/1750-9378-6-19 PMID: 22035468
65. Xi LF, Demers GW, Koutsky LA, Kiviat NB, Kuypers J, Watts DH, et al. Analysis of Human Papillomavirus Type 16 Variants Indicates Establishment of Persistent Infection. J Infect Dis. 1995; 172: 747-755. PMID: 7658068
66. Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, et al. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst. 2006; 98: 1045-1052. doi: 10.1093/jnci/djj297 PMID: 16882941
67. Gurgel APAD, Chagas B, Simas R, do Amaral CM, Nascimento KC, et al. Prevalence of Human Papillomavirus Variants and Genetic Diversity in the L1 Gene and Long Control Region of HPV16, HPV31, and HPV58 Found in North-East Brazil. BioMed Res Int. 2015; 2015: e130828. doi: 10.1155/2015/ 130828
68. Schmitt M, Bravo IG, Snijders PJF, Gissmann L, Pawlita M, Waterboer T. Bead-Based Multiplex Genotyping of Human Papillomaviruses. J Clin Microbiol. 2006; 44: 504-512. doi: 10.1128/JCM.44.2.504- 512.2006 PMID: 16455905
69. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm426485.htm. (accessed December 30, 2014).